18
Mar
2025
See the Photos from TR10 West
Thanks to everyone who attended the TR10 anniversary party Mar. 13 at Adaptive Biotechnologies. The toasts and roasts were funny, perceptive and heartfelt. It was a joyous occasion. Enjoy a few photos. Click to enlarge. Photos by Robert Wade.
18
Mar
2025
See the Photos from TR10 East
Thanks to everyone who attended the TR10 anniversary party Mar. 6 at Alnylam Pharmaceuticals. The toasts and roasts were funny, perceptive and heartfelt. There was a joyful community spirit in the room. Enjoy a few photos. Click to enlarge. Photos by Mike Mejia.
18
Mar
2025
Arbor Survives Winter, Gets $73.9M to Take Gene Editing to the Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2025
CAR-T cell Therapies Made In the Body: Andy Scharenberg on The Long Run
Andy Scharenberg is today’s guest on The Long Run. Andy is the co-founder and CEO of Seattle-based Umoja Biopharma. The company is developing in vivo CAR-T cell therapies. The idea is to use gene therapy, delivered in a single shot, that can reprogram T cells of the immune system to recognize markers on cancer cells and then hunt down cancer... Read More
17
Mar
2025
Curevo Captures $110M to Develop a More Tolerable Shingles Vaccine
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Mar
2025
Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2025
Biotech Legend Retires, Jazz Buys Glioma Drug, & FDA Shakeup
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Mar
2025
Flashback: Q&A on Founding TR
[Dear Readers: This Q&A from the Knight Science Journalism at MIT blog on Feb. 3, 2015 captures my thoughts on founding TR and where biotech was going. Thank you for your support. — Luke ] By Wade Roush For writers, part of the fuss about the Web explosion of the late 1990s was that it was finally possible to cut... Read More
3
Mar
2025
A Woman in the TechBio Arena: Najat Khan on The Long Run
Najat Khan is today’s guest on The Long Run. She is the chief R&D and chief commercial officer of Salt Lake City-based Recursion. The company is one of the first-generation companies that have sought to reinvent drug R&D from the ground up with automated technologies that collect a lot of biological data and then analyze that data with AI algorithms.... Read More
27
Feb
2025
Bluebird Fire Sale, Regeneron’s Gene Therapy for Deafness, & Eikon Raises a Bundle
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Feb
2025
Defend Young Scientists
Biotech thrives on the creative dynamism of young scientists. Always has. Young scientists are under pressure. NIH grants are on hold. If the NIH budget is gutted, and a generation is forced to find other ways to earn a living, then the biotech industry will lose. It might not be clear for the next couple of quarters or next couple... Read More
18
Feb
2025
Defend the FDA
We need a competent, well-supported, tough and independent food and drug regulator in this country. We need that independent cop on the beat so we can have confidence that the medicines, vaccines, diagnostics and devices at the core of modern healthcare have passed the scrutiny of an uncorrupted, scientifically grounded and ethical group of people working in the public interest.... Read More
13
Feb
2025
RFK Jr. in Power, NIH and FDA on the Chopping Block, & Interest Rates Loom Large
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2025
Defend the NIH
Too many people don’t believe anymore in the American Dream. But if you can’t dream big, you can’t accomplish big things. Today, the National Institutes of Health — biomedical science itself — is under attack. It needs us to stand up in its defense. The NIH is an engine of the American Dream. The NIH, with a $47.7 billion a... Read More
11
Feb
2025
Building a Fully Integrated Biopharma For the Muscle: Robert Blum on The Long Run
Robert Blum is today’s guest on The Long Run. Robert is the CEO of South San Francisco-based Cytokinetics. He joined the company back in the beginning in 1998 and became CEO in 2007. This company, and Robert’s career, are emblematic of what this show is about — The Long Run that it takes to develop new medicines. The company has... Read More
6
Feb
2025
Billion Cells Project, Alumis Merges, BMS Cuts Deeper
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2025
Timmerman Report Turns 10
Timmerman Report is 10 years old today. On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual — and fiercely independent — biotech journalism. The past 10 years of biotech have been remarkable. I’ve had a front-row seat. It’s... Read More
30
Jan
2025
Akero Nails MASH Trial, Cargo Crashes, & Maze, Metsera IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2025
Looking at Live Cells and How They Interact at Scale: Mostafa Ronaghi on The Long Run
Mostafa Ronaghi is today’s guest on The Long Run. He is the co-founder and an executive board member at Foster City, Calif.-based Cellanome. Mostafa is a molecular biologist and technology developer. He is an inventor of pyrosequencing methods for DNA sequencing, and is best known for his work as chief technology officer at Illumina during its glory days from 2008-2021.... Read More
22
Jan
2025
Party Like It’s 2015: Celebrate the 10th Anniversary of Timmerman Report
The Timmerman Report is gearing up for the 10th Anniversary. Time to Party! Join a stellar cast of biotech leaders at the TR10 East Coast Party. This free and fun event will celebrate the 10th anniversary of Timmerman Report. Don’t miss the toasts and roasts of TR Founder Luke Timmerman. Listen for a few predictions about the next 10 years of... Read More